| Ytd | -71.21% | |
| 1y | -90.59% |
| Open | 4.52 | Prev Close | 4.48 | Low | 3.85 | High | 4.52 | Mkt Cap | 4.09M |
| Vol | 8.52M | Avg Vol | 54.08K | EPS | 313.20 | P/E | 0.01 | Forward P/E | -0.98 |
| Beta | 0.23 | Short Ratio | 1.62 | Inst. Own | 36.40% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-10 | 50-d Avg | 6.61 | 200-d Avg | 14.79 | 1yr Est | 2.50 |
XAIR News
Gainers Redhill Biopharma (NASDAQ:RDHL) shares increased by 96.7% to $1.3 during Monday's pre-m
Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial-stage
GARDEN CITY, N.Y., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" o
Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 24.6% to $6.42 during Friday's regular
Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 41.4% to $7.29 during Friday's pre-mark
Elastic NV (ESTC) stock rose 21.8% in pre-market trading after reporting strong Q1 results and raisi
Gainers Aethlon Medical (NASDAQ:AEMD) stock rose 50.7% to $3.27 during Thursday's after-market
https://ipsearch.ipaustralia.gov.au/patents/2020393170
Gainers Autonomix Medical (NASDAQ:AMIX) shares moved upwards by 35.9% to $7.3 during Tuesday's
Beyond Air to receive shares representing 19.99% of Univo's issued and outstanding share capital
Beyond Air to receive shares representing 19.99% of Univo's issued and outstanding share capital upo
Beyond Air, Inc. (XAIR) Q1 2027 Earnings Call Transcript
Beyond Air (NASDAQ:XAIR) reported quarterly losses of $(11.00) per share which missed the analyst co
Beyond Air (NASDAQ:XAIR) affirms FY2027 sales outlook from $16.000 million-$18.000 million to $16.00
Reports $1.8 million revenue for quarter ended June 30, 2026; reaffirms revenue guidance of $8 milli
GARDEN CITY, N.Y., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” o
Gainers Universe Pharmaceuticals (NASDAQ:UPC) shares increased by 108.5% to $6.59 during Monday'
VANCOUVER, British Columbia, July 30, 2026 (GLOBE NEWSWIRE) -- Beyond Oil Ltd. (TSX: BOIL) (OTCQB: B
GARDEN CITY, N.Y., July 30, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” o
Gainers Anixa Biosciences (NASDAQ:ANIX) shares rose 10.0% to $3.65 during Friday's pre-market s
Gainers Liminatus Pharma (NASDAQ:LIMN) stock increased by 40.9% to $0.16 during Thursday's pre-
Beyond Air, Inc. (XAIR) Q4 2026 Earnings Call Transcript
U.S. stock futures slipped on Friday after a mixed close on Thursday.
On Friday, Beyond Air (NASDAQ:XAIR) discussed fourth-quarter financial results during its earnings c
Companies Reporting Before The Bell • Beyond Air (NASDAQ:XAIR) is estimated to report quarterly loss
Beyond Air (NASDAQ:XAIR) reported quarterly losses of $(0.77) per share which missed the analyst con
Revenue increased by 107% year-over-year to $7.7 million in the full fiscal year 2026; increased rev
The CNN Fear & Greed Index, measuring market sentiment, showed a slight decline on Thursday, rem
U.S. stock futures are down, but some stocks to watch today include Apogee, BitGo, Cineverse, Synapt
GARDEN CITY, N.Y., June 22, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” o
Special Meeting of Stockholders Scheduled for June 18, 2026 at 4:30 p. m. Eastern Time Proxies have
Beyond Air, Inc. (NASDAQ:XAIR), a commercial-stage medical device and biopharmaceutical company focu
GARDEN CITY, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-s
The Phase 1 trial (NCT05351502) was a clinical proof-of-concept trial that assessed the intratumoral
Updated AACR poster data show continued survival follow-up in heavily pre ‑ treated patients followi
https://x.com/PatentGrants/status/2045229993731776669
GARDEN CITY, N.Y., April 15, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-
Beyond Air, Inc. (NASDAQ:XAIR), a commercial-stage medical device and biopharmaceutical company focu
Beyond Air, Inc. (NASDAQ: XAIR - Get Free Report) was the target of a large drop in short interest i
Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial stage
Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitr
Data was published in the Online Itinerary Planner for the 2026 AACR Annual Meeting, and is schedule
XAIR believes the publication of this article will serve as a catalyst for new scientific research a
GARDEN CITY, N.Y., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” o